Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 2/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | SI | P14410 | 1/20 | 0.41 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | RAD52 | P43351 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 5/20 | 0.39 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20962942 | 0.94 | NAAA (0.55) | FAAHNAAAALDH1A1DGKATSHR | |
| SCHEMBL20500907 | 0.93 | NAAA (0.58) | FAAHNAAADGKATSHRRAD52 | |
| SCHEMBL21202159 | 0.93 | NAAA (0.58) | FAAHNAAADGKATSHRRAD52 | |
| SCHEMBL8914000 | 0.88 | MGAM (0.44) | FAAHNAAAALDH1A1DGKAMGAM | |
| SCHEMBL152233 | 0.85 | ALDH1A1 (0.61) | FAAHNAAAALDH1A1ATMDGKA | |
| SCHEMBL29093455 | 0.83 | ALDH1A1 (0.58) | FAAHNAAAALDH1A1ATMDGKA | |
| Butane SCHEMBL6048840 | 0.83 | ALDH1A1 (0.58) | FAAHNAAAALDH1A1ATMDGKA | |
| SCHEMBL7611107 | 0.83 | ALDH1A1 (0.58) | FAAHNAAAALDH1A1ATMDGKA | |
| SCHEMBL18319913 | 0.81 | NAAA (0.68) | FAAHNAAAALDH1A1ATMDGKA | |
| SCHEMBL5268975 | 0.81 | ALDH1A1 (0.56) | FAAHNAAAALDH1A1ATMDGKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5621063-A | BLOCKING WITH MALONIC ESTER; DEBLOCKING AT LOW TEMPERATURE | HUELS AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | claimed |
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | MAZE THERAPEUTICS, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | MEDSHINE DISCOVERY INC. (CN) | 2017-07-13 | — | — | US | disclosed |
| EP-3150600-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | Medshine Discovery Inc. (CN) | 2017-04-05 | — | — | EP | disclosed |
| US-5621063-A | BLOCKING WITH MALONIC ESTER; DEBLOCKING AT LOW TEMPERATURE | HUELS AKTIENGESELLSCHAFT (DE) | 1997-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11814367-B2 | Inhibitors of glycogen synthase 1 (GYS1) and methods of use thereof | GYS2, GYS1, PYGL | FAAH 4807/4885NAAA 4378/4885ALDH1A1 2458/4885 |
| US-20170197986-A1 | DIHYDROPYRIMIDO LOOP DERIVATIVE AS HBV INHIBITOR | TMBIM6, HAVCR2, HDGF | FAAH 4271/4885NAAA 3369/4885ALDH1A1 4083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.